PharmaEssentia: ROPEG expands across MPNs as 9M 2026 revenue reaches NTD 19.7B
Meno di 1 minuto di lettura
ROPEG’s PV reach exceeds 50 countries, with ET approvals added across four markets in 2026. Revenue reached NTD 19.7B in 9M 2026, while PMF Phase III enrollment and a broader oncology and immunology pipeline support expansion.
Original document: PharmaEssentia Corp. [6446] Slides Release — Nov. 13 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr